Vestal Point Capital LP Raises Stock Holdings in Structure Therapeutics Inc. (NASDAQ:GPCR)

Vestal Point Capital LP boosted its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) by 50.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,725,000 shares of the company’s stock after acquiring an additional 575,000 shares during the quarter. Structure Therapeutics accounts for 2.8% of Vestal Point Capital LP’s portfolio, making the stock its 11th biggest holding. Vestal Point Capital LP owned about 3.01% of Structure Therapeutics worth $46,782,000 as of its most recent SEC filing.

Several other hedge funds also recently bought and sold shares of GPCR. Twinbeech Capital LP lifted its position in shares of Structure Therapeutics by 34.3% during the fourth quarter. Twinbeech Capital LP now owns 28,268 shares of the company’s stock worth $767,000 after purchasing an additional 7,220 shares during the last quarter. Tema Etfs LLC purchased a new position in Structure Therapeutics in the 4th quarter worth about $1,203,000. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Structure Therapeutics by 8.4% during the 4th quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 19,520 shares of the company’s stock valued at $529,000 after buying an additional 1,520 shares in the last quarter. Janus Henderson Group PLC lifted its holdings in Structure Therapeutics by 5.1% during the 4th quarter. Janus Henderson Group PLC now owns 4,159,888 shares of the company’s stock valued at $112,816,000 after buying an additional 203,010 shares in the last quarter. Finally, Ensign Peak Advisors Inc boosted its position in Structure Therapeutics by 67.7% in the 4th quarter. Ensign Peak Advisors Inc now owns 308,241 shares of the company’s stock valued at $8,359,000 after buying an additional 124,456 shares during the period. Institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Trading Up 3.0%

GPCR opened at $25.17 on Monday. The firm has a market cap of $1.44 billion, a price-to-earnings ratio of -34.01 and a beta of -1.69. Structure Therapeutics Inc. has a 12 month low of $13.22 and a 12 month high of $62.74. The stock has a fifty day moving average price of $21.19 and a 200-day moving average price of $26.37.

Structure Therapeutics (NASDAQ:GPCR) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, equities research analysts forecast that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. Citigroup assumed coverage on shares of Structure Therapeutics in a research report on Friday, May 2nd. They set a “buy” rating and a $60.00 target price on the stock. William Blair assumed coverage on Structure Therapeutics in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. Finally, HC Wainwright decreased their target price on Structure Therapeutics from $80.00 to $75.00 and set a “buy” rating for the company in a research report on Monday, May 12th. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $78.00.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.